Acetate salt of buprenorphine and methods for preparing buprenorphine

Patent metadata

Field	Value
Publication number	US-9926329-B2
Application number	US-201715446197-A
Country	US
Kind code	B2
Filing date	Mar 1, 2017
Priority date	Mar 10, 2015
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.

First claim

What is claimed:

1. A solid acetate salt of buprenorphine.

2. The acetate salt of buprenorphine of claim 1 , comprising a hydrate.

3. The acetate salt of buprenorphine of claim 2 , wherein the hydrate is a tetrahydrate.

4. A method for preparing an acetate salt of buprenorphine, comprising the steps of:
(a) contacting buprenorphine free base with a solution comprising acetic acid to form an admixture, wherein the admixture is at a temperature of from about 40° C. to about 80° C.;
(b) optionally filtering the admixture of step (a);
(c) adding an agent to the admixture produced in step (a) or (b) to precipitate the acetate salt of buprenorphine; and
(d) isolating the acetate salt of buprenorphine precipitated in step (c).

5. The method of claim 4 , wherein step (a) comprises contacting the buprenorphine free base with the solution comprising acetic acid in an amount of from about 2 mass equivalents to about 6 mass equivalents relative to the starting mass of the free base.

6. The method of claim 4 , wherein in step (a) the solution comprising acetic acid is an aqueous solution having from about 40 wt % to about 70 wt % acetic acid relative to the weight of the aqueous solution.

7. The method of claim 4 , wherein in step (a) the admixture is at a temperature of from about 45° C. to about 75° C., for a period of time wherein a substantial portion of the buprenorphine free base has dissolved.

8. The method of claim 4 , wherein step (b) comprises filtering the admixture of step (a) in a filtration apparatus.

9. A method for preparing an acetate salt of buprenorphine comprising the steps of:
(a) contacting buprenorphine free base with a solution comprising acetic acid to form an admixture, wherein the admixture is at a temperature of from about 40° C. to about 80° C.;
(b) optionally filtering the admixture of step (a);
(c) adding an agent selected from an anti-solvent, a seed crystal, and combinations thereof to the admixture produced in step (a) or (b) to precipitate the acetate salt of buprenorphine; and
(d) isolating the acetate salt of buprenorphine precipitated in step (c).

10. The method of claim 9 , wherein the agent comprises an anti-solvent present in an amount of from about 0.2 mass equivalents to about 8.0 mass equivalents of anti-solvent relative to the starting mass of free base in step (a).

11. The method of claim 9 , wherein the anti-solvent comprises water.

12. The method of claim 9 , wherein when the agent comprises a seed crystal, the seed crystal comprises an acetate salt of buprenorphine.

13. The method of claim 9 , wherein step (c) comprises adding the agent comprising the seed crystal in an amount of from about 0.1 wt % to about 5.0 wt % of seed crystal relative to the starting mass of the buprenorphine free base in step (a).

14. The method of claim 9 , wherein, when adding the agent comprising the seed crystal to the admixture of step (a) or (b), the admixture of step (a) or (b) is at a temperature of from about 40° C. to about 80° C.

15. The method of claim 9 , wherein, when adding the agent comprising the seed crystal to the admixture of step (a) or (b), the admixture of step (a) or (b) is at a temperature of from about 55° C. to about 65° C.

16. The method of claim 9 , wherein step (c) comprises adding a first amount of the anti-solvent followed by adding the seed crystal.

17. The method of claim 16 , wherein the first amount of the anti-solvent is from about 0.2 mass equivalents to about 2.0 mass equivalents relative to the starting mass of the buprenorphine free base in step (a).

18. The method of claim 16 , wherein step (c) comprises adding a second amount of the anti-solvent after adding the seed crystal.

19. The method of claim 4 , further comprising cooling the admixture to a temperature of about 30° C. or lower following addition of the agent and prior to isolating the acetate salt of buprenorphine in, step (d).

20. The method of claim 4 , further comprising adding a co-solvent to the admixture following the precipitation of step (c) and prior to the isolating of the acetate salt of buprenorphine in step (d).

21. The method of claim 20 , further comprising cooling the admixture to a temperature of about 30° C. or lower following addition of the co-solvent and prior to the isolating of the acetate salt of buprenorphine in step (d).

22. The method of claim 4 , further comprising slurrying the acetate salt of buprenorphine obtained from the isolation of step (d) with a slurrying solution comprising water and an alcohol, and filtering the acetate salt therefrom.

23. A buprenorphine acetate salt product obtained from the method of claim 4 .

24. The product of claim 23 , wherein the buprenorphine acetate salt, product comprises about 0.10 wt % or less of a compound of formula (10):

or a salt thereof.

25. The product of claim 23 , wherein the buprenorphine acetate salt product comprises about 0.10 wt % or less of a compound of formula (11):

or a salt thereof.

26. The product of claim 23 , wherein the buprenorphine acetate salt product comprises about 0.08 wt % or less of a compound of formula (12):

or a salt thereof.

27. The product of claim 26 , wherein the buprenorphine acetate salt product comprises about 0.10 wt % or less of a compound of formula (13):

or a salt thereof.

28. The product of claim 23 , wherein the buprenorphine acetate salt product comprises about 0.10 wt % or less of a compound of formula (14):

or a salt thereof.

29. The product of claim 23 , wherein the buprenorphine acetate salt product comprises about 0.10 wt % or less of a compound of formula (15):

or a salt thereof.

Assignees

• Rhodes Tech

Inventors

• Huntley C Frederick M
• Kataisto Erik Wayne
• Reisch Helge Alfred
• Sharma Archana

Classifications

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61K31/485 Primary

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07D489/12 Primary

  the bridge containing only two carbon atoms · CPC title